Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and ...

Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter ...

In the pediatric expansion, Nuvaxovid achieved its primary efficacy endpoint with clinical efficacy of 78.29% (95% CI: 37.55%, 92.45%) overall at a time when the Delta variant was the predominant ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Novavax ( ($NVAX) ) has risen by 19.30%. Read on to learn why. Novavax has seen a remarkable 19.30% increase in its stock price over the past ...

The EUL has been granted for the Nuvaxovid COVID-19 Vaccine, a novel recombinant, adjuvanted SARS-CoV-2 rS vaccine, which is to be marketed by Novavax in Europe and other markets.

The EC granted CMA for Nuvaxovid to prevent COVID-19 in individuals aged 18 and over in December 2021. In addition to the EC's expanded CMA, India has granted emergency use authorization in the 12 ...

Nuvaxovid is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 mcg antigen and 50 mcg Matrix-M adjuvant) given ...

The Nuvaxovid vaccine would serve as a great response to those anonymous anti-vaccination social media accounts that have kept trying to convince people not to get the Covid-19 mRNA vaccines by ...

Nuvaxovid is distinct from other COVID-19 vaccines currently in use in the UK as it uses recombinant protein-based technology which has been used for many years in the development of vaccines to ...

STATEN ISLAND, N.Y. — The World Health Organization (WHO) issued an emergency use listing (EUL) for another coronavirus (COVID-19) vaccine — Nuvaxovid — it was announced Tuesday. The new ...